Disease relevance of Urofollitropin

• From 1984 through 1991, chorionic gonadotropin, menotropins, and urofollitropin together accounted for no more than one third of the market share of the gonadotrophin class of drugs, whose primary indication is treatment of infertility [1].
• Experience with recombinant FSH in the treatment of male hypogonadotrophic hypogonadism is limited, but the available data suggest that recombinant FSH has a similar efficacy to urine-derived preparations (urofollitropin) [2].
• It remains unclear whether human menopausal gonadotropins have a higher risk of overstimulation and ovarian hyperstimulation syndrome compared to urofollitropin in women with polycystic ovary syndrome [3].

High impact information on Urofollitropin

• OBJECTIVE: To determine the effects of ovarian stimulation with highly purified urofollitropin on oocyte and embryo quality [4].
• This multicentre, open, randomized, study compared the efficacy and safety of recombinant follicle stimulating hormone (rFSH; follitropin alpha) with highly purified urinary human FSH (uFSH; urofollitropin HP) in women undergoing ovulation induction for assisted reproductive techniques [5].
• OBJECTIVE: To assess the performance of Fertinex (urofollitropin; Serono Laboratories, Norwell, MA) in stimulating the development of multiple follicles and initiating subsequent pregnancy in patients undergoing controlled ovarian hyperstimulation (COH) for IVF [6].
• Early follicular phase serum E2 and FSH changes in groups 1 and 2 were compared with changes in nine normal responder controls who were receiving a standard long-protocol GnRH-a/urofollitropin regimen (group 3) [7].
• The relationship between FSH dose and serum level was different for lean and obese PCOS patients after subcutaneously injected urofollitropin CONCLUSIONS: There seems to be a difference in resorption/metabolism between lean and obese PCOS patients with regard to s.c. injected FSH [8].

Biological context of Urofollitropin

• Serum FSH levels in women with polycystic ovary syndrome during ovulation induction using down-regulation and urofollitropin [8].
• To assess and compare its pharmacokinetics with urofollitropin (u-hFSH; Metrodin), extracted from the urine of postmenopausal women, we performed a cross-over study in 12 monkeys [9].
• PATIENT(S): One hundred fifty-six women who underwent 178 assisted reproductive technology (ART) cycles with luteal phase GnRH agonist suppression plus hMG and urofollitropin stimulation [10].
• In patients with WHO group II anovulation, protocols based on recombinant FSH are more effective than conventional protocols using urofollitropin [2].

Anatomical context of Urofollitropin

• Clomiphene, human menopausal gonadotropin, and ovulation stimulation with urofollitropin were compared against gamete intrafallopian transfer, zygote intrafallopian transfer, and in vitro fertilization (assisted reproductive techniques) [11].

Associations of Urofollitropin with other chemical compounds

• After a written informed consent, each woman randomly underwent a long-protocol for ovarian hyperstimulation using gonadotropin-releasing hormone (GnRH)-analog and one of the following recombinant- and urinary-gonadotropins--alpha-follitropin, beta-follitropin or urofollitropin [12].

Analytical, diagnostic and therapeutic context of Urofollitropin

• Molecular composition of two different batches of urofollitropin: analysis by immunofluorimetric assay, radioligand receptor assay and in vitro bioassay [13].
• Human menopausal gonadotropin is comparably effective to urofollitropin in terms of pregnancy outcomes [3].
• Comparative studies and a meta-analysis have shown that recombinant FSH is more effective than urofollitropin for controlled ovarian stimulation in women undergoing ART [2].

References